×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Diverticular Disease Market Share

ID: MRFR/Pharma/4239-HCR
105 Pages
Rahul Gotadki
October 2025

Diverticular Disease Market Research Report Information Type (Diverticulosis, Diverticulitis) Treatment (Medication, Supportive Care, Surgery) Diagnosis (CT Scan, Ultrasound, Urine Test, Blood Test) End User (Hospitals, Specialty Centers) – Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Diverticular Disease Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Diverticular Disease Market Share Analysis

The diverticular disease market is changing significantly due to the improvement of old age populations [sic], dietary habits, and medical understanding (Euromonitor International 2013). On the other hand, there is an ever-constant need for efficient treatments and strategies, such as those that could help control symptoms caused by diverticulitis (Canavan et al., 2014). Additionally, today's Diverticular Disease Market experiences a greater amount of innovative therapeutic options beyond traditional approaches (Tursi et al., 2015). Consequently, although dietary changes have remained central to managing symptoms together with antibiotics and anti-inflammatory agents, there has been an increasing focus on probiotics as against symbiotic preparations aimed at restoring gut microbiota balance (Tursi et al., 2015). The market is also experiencing a surge in the use of minimally invasive procedures for diverticular disease, particularly with respect to complications such as diverticulitis. Laparoscopic surgeries and other endoscopic interventions have become more common, allowing patients to enjoy less invasive treatment options, shorter recovery periods, and better postoperative outcomes. Partnerships between pharmaceutical companies, medical device manufacturers, and research institutions are driving the Diverticular Disease Market. These partnerships create a collaborative environment that facilitates the exchange of information and resources aimed at accelerating innovation in research and development for new products. There has been increasing adoption of telemedicine and mobile applications for managing diverticular disease as digital health solutions gain traction in healthcare. Remote consultations, monitoring, and patient education are possible through these technologies, making healthcare services more accessible while empowering individuals to take part in their healing processes. Demographic changes towards an aging population impact the Diverticular Disease Market as the prevalence tends to grow with age. As a result, pharmaceutical companies have increased their research and development efforts targeting this specific category of patients who are older compared to others in society. These evolving age-specific therapy approaches consider morbidity as well as potential complications among geriatric individuals.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

Market Summary

As per Market Research Future analysis, the Diverticular Disease Market Size was estimated at 1660.26 USD Million in 2024. The Diverticular Disease industry is projected to grow from USD 1809.78 Million in 2025 to USD 3832.62 Million by 2035, exhibiting a compound annual growth rate (CAGR) of 7.86% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Diverticular Disease Market is experiencing notable growth driven by various factors and advancements.

  • The rising prevalence of diverticular disease is becoming increasingly evident, particularly in North America. Advancements in diagnostic technologies are enhancing early detection and management of diverticular conditions. The integration of telemedicine solutions is facilitating access to care, especially in the Asia-Pacific region. Key market drivers include the increasing aging population and rising awareness and education regarding diverticular disease.

Market Size & Forecast

2024 Market Size 1660.26 (USD Million)
2035 Market Size 3832.62 (USD Million)
CAGR (2025 - 2035) 7.86%
Largest Regional Market Share in 2024 North America

Major Players

<p>AbbVie (US), Bristol-Myers Squibb (US), Johnson &amp; Johnson (US), Merck &amp; Co. (US), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (JP), AstraZeneca (GB)</p>

Market Trends

The Diverticular Disease Market is currently experiencing notable transformations, driven by a combination of demographic shifts and evolving healthcare paradigms. An increasing prevalence of diverticular disease, particularly among aging populations, appears to be influencing demand for innovative treatment options. Furthermore, advancements in diagnostic technologies and therapeutic interventions are likely to enhance patient outcomes, thereby fostering market growth. The integration of telemedicine and digital health solutions may also play a pivotal role in improving access to care, particularly in underserved regions. Moreover, the rising awareness surrounding diverticular disease and its management is contributing to a more informed patient population. Educational initiatives and outreach programs seem to be effective in promoting early diagnosis and preventive measures. As healthcare systems adapt to these changes, the Diverticular Disease Market is poised for continued evolution, with potential opportunities for stakeholders to engage in research and development efforts aimed at addressing unmet medical needs. This dynamic landscape suggests a promising future for both patients and healthcare providers alike.

Rising Prevalence of Diverticular Disease

The increasing incidence of diverticular disease, particularly among older adults, is driving demand for effective treatment options. As populations age, healthcare providers are likely to focus on developing tailored therapies that address the unique needs of this demographic.

Advancements in Diagnostic Technologies

Innovations in diagnostic tools are enhancing the ability to detect diverticular disease at earlier stages. Improved imaging techniques and non-invasive methods may facilitate timely interventions, potentially leading to better patient outcomes.

Integration of Telemedicine Solutions

The adoption of telemedicine is transforming how patients access care for diverticular disease. Remote consultations and digital health platforms could improve patient engagement and adherence to treatment plans, particularly in rural or underserved areas.

Diverticular Disease Market Market Drivers

Market Growth Projections

The Global Diverticular Disease Market Industry is projected to experience substantial growth over the next decade. With a market value of 1.83 USD Billion in 2024, it is anticipated to reach 3.94 USD Billion by 2035, reflecting a compound annual growth rate of 7.22% from 2025 to 2035. This growth trajectory indicates a robust demand for healthcare services and interventions related to diverticular disease. Factors contributing to this expansion include the rising prevalence of the disease, advancements in diagnostic and treatment options, and increased healthcare expenditure. Such projections highlight the importance of strategic planning and investment in the healthcare sector.

Rising Healthcare Expenditure

The Global Diverticular Disease Market Industry is positively impacted by the rising healthcare expenditure across various regions. Governments and private sectors are increasingly investing in healthcare infrastructure and services, which enhances access to treatment for diverticular disease. This trend is particularly evident in developed nations, where healthcare budgets are expanding to accommodate the growing burden of chronic diseases. As healthcare spending rises, it is anticipated that the market will experience robust growth, with a projected CAGR of 7.22% from 2025 to 2035. This financial commitment underscores the importance of addressing diverticular disease within broader healthcare strategies.

Growing Awareness and Education

Increasing awareness and education regarding diverticular disease are pivotal drivers of the Global Diverticular Disease Market Industry. Public health campaigns and educational initiatives have been instrumental in informing individuals about the risk factors and symptoms associated with the condition. This heightened awareness encourages early diagnosis and treatment, ultimately leading to better health outcomes. Healthcare professionals are also becoming more knowledgeable about the disease, which may contribute to improved patient management. As awareness continues to grow, the market is likely to see an uptick in demand for therapeutic options and preventive measures.

Advancements in Diagnostic Techniques

Technological innovations in diagnostic methods are significantly influencing the Global Diverticular Disease Market Industry. Enhanced imaging techniques, such as high-resolution CT scans and MRI, allow for more accurate detection and assessment of diverticular disease. These advancements facilitate timely diagnosis, which is crucial for effective management and treatment. As healthcare providers increasingly adopt these technologies, the market is expected to benefit from improved patient outcomes and reduced healthcare costs. The integration of artificial intelligence in diagnostics may further streamline processes, potentially increasing market growth as more patients receive appropriate care.

Rising Prevalence of Diverticular Disease

The Global Diverticular Disease Market Industry is experiencing a notable increase in prevalence, particularly among aging populations. As individuals age, the risk of developing diverticular disease escalates, leading to a higher demand for treatment options. In 2024, the market is projected to reach 1.83 USD Billion, reflecting the growing need for healthcare services and interventions. This trend is likely to continue as the global population ages, with estimates suggesting that by 2035, the market could expand to 3.94 USD Billion. Such growth underscores the importance of addressing diverticular disease in public health initiatives.

Increased Research and Development Activities

The Global Diverticular Disease Market Industry is witnessing a surge in research and development activities aimed at understanding the disease better and developing innovative treatment options. Pharmaceutical companies and research institutions are focusing on creating new therapies and improving existing ones, which could lead to more effective management of diverticular disease. This emphasis on R&D is likely to result in the introduction of novel medications and interventions, thereby expanding the market. As the understanding of diverticular disease evolves, it is expected that the market will continue to grow, driven by advancements in treatment methodologies.

Market Segment Insights

By Disease Type: Diverticulitis (Largest) vs. Diverticulosis (Fastest-Growing)

<p>In the Diverticular Disease Market, Diverticulitis holds the largest market share, driven by the increasing prevalence of acute episodes requiring medical intervention. Diverticulosis, although not producing significant symptoms in many patients, is prevalent in older demographics, indirectly boosting overall market growth. Diverticular Bleeding, while a critical concern, contributes less to the segment share compared to its counterparts. This distribution highlights the need for targeted treatments and awareness surrounding the conditions.</p>

<p>Diverticulitis (Dominant) vs. Diverticulosis (Emerging)</p>

<p>Diverticulitis is characterized by inflammation and diverticular complications, making it a dominant segment within the Diverticular Disease Market. Patients often seek immediate care, leading to higher healthcare expenditures and emphasis on treatment development. On the other hand, Diverticulosis, recognized as an emerging focus, is gaining traction due to rising awareness about preventative measures, dietary impacts, and lifestyle modifications. As healthcare professionals increasingly recognize the importance of managing asymptomatic cases to prevent progression to Diverticulitis or bleeding, the segment is expected to experience substantial growth in diagnosis and management strategies.</p>

By Treatment Type: Medication (Largest) vs. Surgery (Fastest-Growing)

<p>In the Diverticular Disease Market, the treatment type segment is primarily dominated by medication, which holds the largest market share. This encompasses both over-the-counter and prescription drugs aimed at managing symptoms and preventing complications. Surgery follows as a significant treatment option, often considered when medication fails to provide relief, especially in cases of severe diverticulitis or complications such as abscesses. Dietary management and lifestyle changes, while crucial for long-term management, represent smaller portions of the market share. The growth trends in this segment indicate a notable shift towards surgical procedures as a faster-growing option. Increased awareness and diagnosis of diverticular disease are driving patients towards surgical interventions, particularly minimally invasive techniques. The aging population, coupled with rising prevalence rates of diverticular complications, is propelling this growth. Additionally, advancements in medical technology and surgical practices are enhancing patient outcomes, fostering further adoption of surgical treatments.</p>

<p>Medication (Dominant) vs. Surgery (Emerging)</p>

<p>Medication serves as the dominant treatment in the Diverticular Disease Market, primarily focusing on alleviating symptoms and preventing future complications. Its appeal lies in the accessibility and convenience for patients, as many medications can be managed at home, thus reducing the need for hospital visits. Conversely, surgery is emerging as a key treatment option, particularly for patients who do not respond to medical management or experience recurrent diverticulitis. The surgical landscape is evolving with the introduction of minimally invasive techniques, which offer reduced recovery times and lower complication rates. This shift is increasingly favored among both patients and healthcare providers, highlighting a trend toward more aggressive intervention strategies in managing advanced diverticular disease.</p>

By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

<p>In the Diverticular Disease Market, the distribution of patient demographics highlights age group as the largest segment. Older adults, particularly those aged 50 and above, represent a significant proportion of patients diagnosed with diverticular disease, due to the association of the disease with aging. Conversely, gender is emerging as a fast-growing segment in the market, with a notable increase in diagnoses among females attributed to lifestyle changes.</p>

<p>Age Group: 50+ (Dominant) vs. Gender: Female (Emerging)</p>

<p>Patients aged 50 and above dominate the Diverticular Disease Market due to their increased susceptibility to gastrointestinal disorders, with the prevalence rising sharply in this demographic. Lifestyle factors, including diet and activity levels, have impacted the growing incidence rates among older adults. Meanwhile, the emerging female demographic is showing a significant rise in diagnoses, likely driven by increased health awareness and changes in medical practices that encourage screening. This trend indicates a shift in how gender is understood in the context of diverticular disease, revealing the need for tailored treatments and management plans that address gender-specific health concerns.</p>

By Severity Level: Moderate (Largest) vs. Severe (Fastest-Growing)

<p>The Diverticular Disease Market displays a distinct segmentation based on severity levels, where moderate cases dominate the market share compared to mild and severe cases. Mild cases, while prevalent, represent a smaller portion of the market due to lower healthcare interventions required. Conversely, moderate severity levels drive a significant portion of healthcare expenses and patient attention, underscoring their importance in healthcare strategies. Growth trends indicate that the severe segment is rapidly expanding, propelled by increasing awareness and advancements in medical technologies. The rise in diagnostic capabilities and treatment options for severe cases is contributing to this surge. Furthermore, demographics, including an aging population and changing dietary habits leading to serious forms of diverticular disease, are key drivers behind the acceleration of the severe segment.</p>

<p>Moderate (Dominant) vs. Severe (Emerging)</p>

<p>In the Diverticular Disease Market, the moderate severity level is seen as the dominant segment due to its significant patient population and healthcare demands. This segment encompasses a wide range of clinical presentations that necessitate regular monitoring and potential interventions, which increasingly captures the attention of healthcare providers. In contrast, the severe segment is emerging as a key player, fueled by increased diagnosis and the urgency of management associated with acute episodes. Patients classified as severe often experience more complex treatment regimens and require specialized care, resulting in heightened healthcare utilization. As awareness of diverticular disease grows, both segments are likely to see shifts in treatment protocols, further influencing their market trajectories.</p>

By Healthcare Setting: Outpatient (Largest) vs. Inpatient (Fastest-Growing)

<p>The healthcare setting segment in the diverticular disease market is characterized by three primary categories: Outpatient, Inpatient, and Emergency Care. Among these, the Outpatient setting holds the largest share due to the preference for less invasive treatment options and the increasing prevalence of diverticular disease, which allows for effective management in outpatient facilities. In contrast, Inpatient care is witnessing rapid growth, driven by the need for surgeries and advanced treatments for severe cases, as well as increasing healthcare costs and resource allocation for hospitalized patients needing immediate attention.</p>

<p>Outpatient (Dominant) vs. Inpatient (Emerging)</p>

<p>The Outpatient setting remains the dominant choice for managing diverticular disease due to its cost-effectiveness and convenience for patients. Patients prefer outpatient care because it minimizes disruptions to daily life, allowing for flexible scheduling and reduced recovery times. On the other hand, the Inpatient segment is classified as an emerging area, reflecting the shift towards managing more complicated cases in a hospital environment. Factors such as an aging population, increased rates of complications, and advancements in surgical techniques are amplifying the demand for inpatient care. As more patients present with severe diverticular disease, the inpatient setting will likely see continued growth, addressing complex cases that require surgical interventions and multidisciplinary approaches.</p>

Get more detailed insights about Diverticular Disease Market Research Report - Forecast to 2035

Regional Insights

North America : Market Leader in Healthcare

North America is poised to maintain its leadership in the Diverticular Disease market, holding a significant market share of $830.13M in 2024. The region's growth is driven by increasing prevalence of diverticular disease, advancements in treatment options, and robust healthcare infrastructure. Regulatory support and innovative therapies are further propelling market demand, making it a focal point for investment and research in gastrointestinal health. The competitive landscape in North America is characterized by the presence of major players such as AbbVie, Johnson & Johnson, and Merck & Co. These companies are actively engaged in developing new therapies and expanding their market reach. The U.S. remains the leading country, supported by a strong emphasis on research and development, ensuring that North America continues to be at the forefront of advancements in the treatment of diverticular disease.

Europe : Emerging Market with Growth Potential

Europe's Diverticular Disease market is valued at $550.09M, reflecting a growing awareness and diagnosis of gastrointestinal disorders. The region benefits from a well-established healthcare system and increasing investments in medical research. Regulatory frameworks are evolving to support innovative treatments, which is expected to drive market growth. The rising geriatric population and lifestyle changes are also contributing to the demand for effective therapies in this sector. Leading countries in Europe include Germany, France, and the UK, where healthcare expenditure is high, and access to advanced medical technologies is prevalent. Key players like AstraZeneca and Bristol-Myers Squibb are focusing on expanding their portfolios in this market. The competitive landscape is becoming increasingly dynamic, with new entrants and collaborations enhancing treatment options for patients suffering from diverticular disease.

Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region, with a market size of $220.05M, is witnessing significant growth in the Diverticular Disease sector. Factors such as rising healthcare awareness, increasing disposable incomes, and a growing aging population are driving demand for effective treatment options. Regulatory bodies are also becoming more supportive of innovative therapies, which is expected to enhance market dynamics in the coming years. The region's diverse healthcare landscape presents both challenges and opportunities for market players. Countries like Japan, China, and Australia are leading the charge in this market, with a focus on improving healthcare access and treatment options. Key players such as Takeda Pharmaceutical are actively investing in research and development to cater to the growing needs of patients. The competitive landscape is evolving, with both local and international companies vying for market share, making Asia-Pacific a vibrant hub for healthcare innovation.

Middle East and Africa : Resource-Rich Frontier for Healthcare

The Middle East and Africa region, valued at $60.0M, is gradually emerging as a significant player in the Diverticular Disease market. The growth is driven by increasing healthcare investments, rising awareness of gastrointestinal disorders, and improving healthcare infrastructure. Regulatory bodies are beginning to implement frameworks that support the introduction of new therapies, which is expected to enhance market growth in the region. The demand for effective treatments is on the rise, particularly in urban areas. Leading countries in this region include South Africa and the UAE, where healthcare systems are evolving rapidly. The presence of key players is still developing, but companies are increasingly focusing on expanding their reach in this market. The competitive landscape is characterized by a mix of local and international firms, creating opportunities for collaboration and innovation in the treatment of diverticular disease.

Key Players and Competitive Insights

The Diverticular Disease Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie (US), Johnson & Johnson (US), and Merck & Co. (US) are actively engaged in enhancing their product portfolios and expanding their market reach. AbbVie (US) has positioned itself as a leader in biologics, focusing on developing targeted therapies that address the underlying mechanisms of diverticular disease. Meanwhile, Johnson & Johnson (US) emphasizes a diversified approach, integrating surgical solutions with pharmaceutical advancements to provide comprehensive care. Merck & Co. (US) appears to be concentrating on research and development, particularly in the realm of novel therapeutics that could redefine treatment paradigms.

The business tactics employed by these companies reflect a commitment to optimizing supply chains and localizing manufacturing to enhance responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive innovation and set industry standards, thereby shaping the overall market dynamics.

In November 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel monoclonal antibody aimed at treating diverticulitis. This collaboration is expected to leverage both companies' expertise in immunology and could potentially accelerate the development timeline, positioning AbbVie (US) at the forefront of therapeutic advancements in this area. The strategic importance of this partnership lies in its potential to enhance AbbVie’s product pipeline and reinforce its competitive edge in the market.

In October 2025, Johnson & Johnson (US) launched a new digital health platform designed to support patients with diverticular disease through personalized treatment plans and real-time monitoring. This initiative reflects a growing trend towards digitalization in healthcare, aiming to improve patient outcomes and engagement. By integrating technology into its offerings, Johnson & Johnson (US) not only enhances its service delivery but also strengthens its brand loyalty among patients and healthcare providers.

In September 2025, Merck & Co. (US) completed the acquisition of a small biotech firm specializing in microbiome research, which is increasingly recognized for its role in gastrointestinal health. This acquisition is strategically significant as it allows Merck & Co. (US) to diversify its research capabilities and explore innovative treatment options that could address the complexities of diverticular disease. The integration of microbiome insights into their therapeutic development could lead to groundbreaking advancements in patient care.

As of December 2025, the competitive trends in the Diverticular Disease Market are increasingly defined by digital transformation, sustainability initiatives, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, innovative therapies, and reliable supply chains, suggesting a shift towards a more sophisticated and patient-centered market landscape.

Key Companies in the Diverticular Disease Market market include

Industry Developments

    • In January, Emmaus Life Sciences has announced the results to be under the preliminary focus. It has been observed the first patient with the company focus has attempted to make the study of the diverticulitis treatment (2020).
    • In 2020, May, Hikma Pharmaceuticals PLC. has launched the Dicyclomine Hydrochloride oral solution for the better treatment of the various inflammatory diagnosis of bowel diseases.

 

Future Outlook

Diverticular Disease Market Future Outlook

<p>The Diverticular Disease Market is projected to grow at a 7.86% CAGR from 2024 to 2035, driven by increasing prevalence, advancements in treatment options, and rising awareness.</p>

New opportunities lie in:

  • <p>Development of targeted biologic therapies for diverticular disease</p>
  • <p>Expansion of telehealth services for patient management</p>
  • <p>Investment in AI-driven diagnostic tools for early detection</p>

<p>By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.</p>

Market Segmentation

Diverticular Disease Market Disease Type Outlook

  • Diverticulitis
  • Diverticulosis
  • Diverticular Bleeding

Diverticular Disease Market Severity Level Outlook

  • Mild
  • Moderate
  • Severe

Diverticular Disease Market Treatment Type Outlook

  • Medication
  • Surgery
  • Dietary Management
  • Lifestyle Changes

Diverticular Disease Market Healthcare Setting Outlook

  • Outpatient
  • Inpatient
  • Emergency Care

Diverticular Disease Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Socioeconomic Status

Report Scope

MARKET SIZE 2024 1660.26(USD Million)
MARKET SIZE 2025 1809.78(USD Million)
MARKET SIZE 2035 3832.62(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.86% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (JP), AstraZeneca (GB)
Segments Covered Disease Type, Treatment Type, Patient Demographics, Severity Level, Healthcare Setting
Key Market Opportunities Advancements in minimally invasive surgical techniques enhance treatment options in the Diverticular Disease Market.
Key Market Dynamics Rising prevalence of diverticular disease drives demand for innovative treatment options and enhanced patient management strategies.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

  1. Report Prologue
  2. Market Introduction
    1. Definition
    2. Scope of the Study
      1. Research Objective
      2. Assumptions
      3. Limitations
  3. Research Methodology
    1. Introduction
    2. Primary Research
    3. Secondary research
    4. Market Size Estimation
  4. Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Challenges
    5. Macroeconomic Indicators
    6. Technology Trends & Assessment
  5. Market Factor Analysis
    1. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
    2. Value Chain Analysis
    3. Investment Feasibility Analysis
    4. Pricing Analysis
  6. Global Diverticular Disease Market, by Type
    1. Introduction
    2. Diverticulosis
      1. Market Estimates & Forecast, 2020-2027
    3. Diverticulitis
      1. Market Estimates & Forecast, 2020-2027
    4. Diverticular Bleeding
      1. Market Estimates & Forecast, 2020-2027
  7. Global Diverticular Disease Market, by Diagnosis
    1. Introduction
    2. Barium X-ray
      1. Market Estimates & Forecast, 2020-2027
    3. Liver Function Test
      1. Market Estimates & Forecast, 2020-2027
    4. Stool Test
      1. Market Estimates & Forecast, 2020-2027
    5. CT Scan
      1. Market Estimates & Forecast, 2020-2027
    6. Blood Test
      1. Market Estimates & Forecast, 2020-2027
    7. Urine Test
      1. Market Estimates & Forecast, 2020-2027
    8. Ultrasound
      1. Market Estimates & Forecast, 2020-2027
    9. Others
      1. Market Estimates & Forecast, 2020-2027
  8. Global Diverticular Disease Market, by Treatment
    1. Introduction
    2. Medications
      1. Antibiotics
      2. Penicillin Antibiotic
      3. Dietary Supplements
      4. Market Estimates & Forecast, 2020-2027
    3. Supportive Care
      1. IV fluids
    4. Surgery
      1. Market Estimates & Forecast, 2020-2027
  9. Global Diverticular Disease Market, by End User
    1. Introduction
    2. Hospitals
      1. Market Estimates & Forecast, 2020-2027
    3. Specialty centers
      1. Market Estimates & Forecast, 2020-2027
    4. Research centers
      1. Market Estimates & Forecast, 2020-2027
  10. Global Diverticular Disease Market, by Region
    1. Introduction
    2. Americas
      1. North America
      2. South America
    3. Europe
      1. Western Europe
      2. Eastern Europe
    4. Asia Pacific
      1. Japan
      2. China
      3. India
      4. Australia
      5. Republic of Korea
      6. Rest of Asia Pacific
    5. The Middle East & Africa
      1. United Arab Emirates
      2. Saudi Arabia
      3. Oman
      4. Kuwait
      5. Qatar
      6. Rest of the Middle East & Africa
  11. Company Landscape
    1. Introduction
    2. Market Share Analysis
    3. Key Development & Strategies
      1. Key Developments
  12. Company Profiles
    1. Abbott Laboratories
      1. Company Overview
      2. Product Overview
      3. Financials
      4. SWOT Analysis
    2. Synergy Pharmaceuticals, Inc.
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
      5. SWOT Analysis
    3. Sucampo Pharmaceuticals, Inc.
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Development
      5. SWOT Analysis
    4. Valeant Pharmaceuticals International, Inc.
      1. Company Overview
      2. Product/Business Segment Overview
      3. Financial Overview
      4. Key Development
      5. SWOT Analysis
    5. Ardelyx, Inc.
      1. Company Overview
      2. Product Overview
      3. Financial overview
      4. Key Developments
    6. Astellas Pharma Inc.
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
    7. Novartis AG
      1. Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    8. Others
  13. MRFR Conclusion
    1. Key Findings
      1. From CEO’s View Point
      2. Unmet Needs of the Market
    2. Key Companies to Watch
    3. Prediction of Pharmaceutical Industry
  14. Appendix
  15. LIST OF TABLES
  16. Diverticular Disease Industry Synopsis, 2020-2027
  17. Global Diverticular Disease Market Estimates and Forecast, 2020-2027, (USD Million)
  18. Global Diverticular Disease Market by Region, 2020-2027, (USD Million)
  19. Global Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  20. Global Diverticular Disease Market by Diagnosis, 2020-2027, (USD Million)
  21. Global Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  22. North America Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  23. North America Diverticular Disease Market by Diagnosis, 2020-2027, (USD Million)
  24. North America Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  25. US Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  26. US Diverticular Disease Market by Diagnosis, 2020-2027, (USD Million)
  27. US Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  28. Canada Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  29. Canada Diverticular Disease Market by Diagnosis, 2020-2027, (USD Million)
  30. Canada Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  31. South America Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  32. South America Diverticular Disease Market by Diagnosis, 2020-2027, (USD Million)
  33. South America Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  34. Europe Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  35. Europe Diverticular Disease Market by Diagnosis, 2020-2027, (USD Million)
  36. Europe Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  37. Western Europe Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  38. Western Europe Diverticular Disease Market by diagnosis, 2020-2027, (USD Million)
  39. Western Europe Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  40. Eastern Europe Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  41. Eastern Europe Diverticular Disease Market by diagnosis, 2020-2027, (USD Million)
  42. Eastern Europe Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  43. Asia Pacific Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  44. Asia Pacific Diverticular Disease Market by diagnosis, 2020-2027, (USD Million)
  45. Asia Pacific Diverticular Disease Market by End Users, 2020-2027, (USD Million)
  46. Middle East & Africa Diverticular Disease Market by Treatment, 2020-2027, (USD Million)
  47. Middle East & Africa Diverticular Disease Market by diagnoses, 2020-2027, (USD Million)
  48. Middle East & Africa Diverticular Disease Market by End Users, 2020-2027, (USD Million)
    1.  
  49. LIST OF FIGURES
  50. Research Process
  51. Segmentation for Global Diverticular Disease Market
  52. Segmentation Market Dynamics for Diverticular Disease Market
  53. Global Diverticular Disease Market Share, by Treatment 2020
  54. Global Diverticular Disease Market Share, by Diagnosis 2020
  55. Global Diverticular Disease Market Share, by End Users, 2020
  56. Global Diverticular Disease Market Share, by Region, 2020
  57. North America Diverticular Disease Market Share, by Country, 2020
  58. Europe Diverticular Disease Market Share, by Country, 2020
  59. Asia Pacific Diverticular Disease Market Share, by Country, 2020
  60. Middle East & Africa Diverticular Disease Market Share, by Country, 2020
  61. Global Diverticular Disease Market: Company Share Analysis, 2020 (%)
  62. Abbott Laboratories: Key Financials
  63. Abbott Laboratories: Segmental Revenue
  64. Abbott Laboratories: Geographical Revenue
  65. Synergy Pharmaceuticals, Inc.: Key Financials
  66. Synergy Pharmaceuticals, Inc.: Segmental Revenue
  67. Synergy Pharmaceuticals, Inc.: Geographical Revenue
  68. Sucampo Pharmaceuticals, Inc.: Key Financials
  69. Sucampo Pharmaceuticals, Inc.: Segmental Revenue
  70. Sucampo Pharmaceuticals, Inc.: Geographical Revenue
  71. Novartis AG: Key Financials
  72. Novartis AG: Segmental Revenue
  73. Novartis AG: Geographical Revenue
  74. GlaxoSmithKline plc: Key Financials
  75. GlaxoSmithKline plc: Segmental Revenue
  76. GlaxoSmithKline plc. Geographical Revenue
  77. Ardelyx, Inc.: Key Financials
  78. Ardelyx, Inc.: Segmental Revenue
  79. Ardelyx, Inc.: Geographical Revenue
  80. Astellas Pharma Inc.: Key Financials
  81. Astellas Pharma Inc.: Segmental Revenue
  82. Astellas Pharma Inc.: Geographical Revenue

Diverticular Disease Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓